PMID- 38354749
OWN - NLM
STAT- Publisher
LR  - 20240214
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2024 Feb 14
TI  - Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in 
      Papillary Thyroid Carcinoma.
LID - 10.1055/a-2255-5718 [doi]
AB  - Interleukin-18 (IL-18) is a proinflammatory cytokine that primarily stimulates 
      the Th1 immune response. IL-18 exhibits anticancer activity and has been 
      evaluated in clinical trials as a potential cancer treatment. However, evidence 
      suggests that it may also facilitate the development and progression of some 
      cancers. So far, the impact of IL-18 on papillary thyroid cancer (PTC) has not 
      been investigated. In this study, we found that the expression of IL-18 was 
      significantly increased in PTC compared to normal thyroid tissue. Elevated IL-18 
      expression was closely associated with lymphovascular invasion and lymph node 
      metastases. Furthermore, compared to PTC patients with no nodal metastasis, serum 
      IL-18 levels were slightly increased in patients with 1-4 nodal metastases and 
      significantly elevated in patients with 5 or more nodal metastases. The 
      pro-metastatic effect of IL-18 may be attributed to the simultaneous increase in 
      the expression of S100A10, a known factor that is linked to nodal metastasis in 
      PTC. In addition, the activation of several pathways, such as the intestinal 
      immune network for lgA production and Staphylococcus aureus infection, may be 
      involved in the metastasis process. Taken together, IL-18 may trigger 
      pro-metastatic activity in PTC. Therefore, suppressing the function of IL-18 
      rather than enhancing it appears to be a reasonable strategy for treating 
      aggressive PTC.
CI  - Thieme. All rights reserved.
FAU - Chun, Wang
AU  - Chun W
AD  - Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
FAU - Lu, Meiyin
AU  - Lu M
AD  - Graduate School, Shantou University Medical College, Shantou, China.
AD  - Department of Biobank, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, 
      China.
FAU - Chen, Jiakang
AU  - Chen J
AD  - Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
FAU - Li, Jian
AU  - Li J
AD  - Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
AD  - State Key Laboratory of Chemical Oncogenomics, Peking University Shenzhen 
      Graduate School, Shenzhen, China.
LA  - eng
PT  - Journal Article
DEP - 20240214
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
SB  - IM
COIS- The authors declare that they have no conflict of interest.
EDAT- 2024/02/15 00:42
MHDA- 2024/02/15 00:42
CRDT- 2024/02/14 19:03
PHST- 2024/02/15 00:42 [medline]
PHST- 2024/02/15 00:42 [pubmed]
PHST- 2024/02/14 19:03 [entrez]
AID - 10.1055/a-2255-5718 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2024 Feb 14. doi: 10.1055/a-2255-5718.